The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Pezzolo E., Di Leo S., Miceli P., Sernicola A., Naldi L.
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- Dermatol Reports (2026)
- Reported sample size
- 609
- Source database
- Europe PMC
- PMID
- 40590534
- PMCID
- PMC13022960
- DOI
- 10.4081/dr.2025.10112
Abstract (original English)
Mesenchymal stem cell (MSC) therapy holds promise for treating immune-mediated inflammatory skin diseases (IMIDs), particularly when conventional therapies are ineffective. Encouraged by their immunomodulatory capabilities and potential for disease modification, different clinical trials are investigating the efficacy and safety of MSCs in single IMIDs. This review aims to summarize the application of MSCs in IMIDs and explore their future clinical potential. We reviewed published studies from January 2016 to January 2024 on MSC treatment for IMIDs. We retrieved 18 clinical trials and 5 observational studies, encompassing 609 patients with psoriasis, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), alopecia areata (AA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE). Improvements or complete remission were observed in up to 100% of cases for AA, SSc, and SLE, though complete remission rates were less frequent than improvement rates, ranging from 0% in AD to 50% in CSU. Adverse events (AEs) were generally mild; moderate-severe AEs were uncommon (4% in psoriasis, 2.6% in SLE, and 0.7% in SSc), and deaths from all causes were rare (6 patients with SSc and 15 patients with SLE). In conclusion, MSC therapy shows promising results in terms of at least partial clinical improvement for most IMIDs. Its effect is achievable after a single or a few administra
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
DKK3-CKAP4 signaling drives fibroimmune remodeling and hair follicle miniaturization in androgenetic alopecia
Meta-analysis on Hair Loss, Hair Regeneration, published in Theranostics (2026) — summary generated from the PubMed abstract.
- 2026
Theranostics - Level AMeta-analysisEurope PMC
Systematic review and meta-analysis of the use of micrografting technology in humans
Meta-analysis with a reported sample of 24 on Chronic Wound, Burns, Hair Loss, published in J Int Med Res (2025) — summary generated from the PubMed abstract.
- 2025
- n = 24
J Int Med Res1 citations - Level ASystematic ReviewEurope PMC
Therapeutic potential of stem cell-derived exosomes in hair regeneration: A systematic review
Systematic Review on Hair Loss, Hair Regeneration, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells2 citations - Level ASystematic ReviewPubMed
Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources.
Systematic Review on Hair Loss, Hair Regeneration, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.
- 2025
Clin Cosmet Investig Dermatol6 citations - Level ASystematic ReviewEurope PMC
Exosome-Based Therapies for Alopecia Areata: A Systematic Review of Clinical and Experimental Evidence
Systematic Review on Scar, Hair Loss, Hair Regeneration, Chronic Inflammation, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
Int J Mol Sci